227 related articles for article (PubMed ID: 31888448)
1. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre.
Negro A; Sciattella P; Rossi D; Guglielmetti M; Martelletti P; Mennini FS
J Headache Pain; 2019 Dec; 20(1):120. PubMed ID: 31888448
[TBL] [Abstract][Full Text] [Related]
2. Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.
Silberstein SD; Lee L; Gandhi K; Fitzgerald T; Bell J; Cohen JM
Headache; 2018 Nov; 58(10):1579-1592. PubMed ID: 30375650
[TBL] [Abstract][Full Text] [Related]
3. Cost of Chronic and Episodic Migraine. A pilot study from a tertiary headache centre in northern Italy.
Berra E; Sances G; De Icco R; Avenali M; Berlangieri M; De Paoli I; Bolla M; Allena M; Ghiotto N; Guaschino E; Cristina S; Tassorelli C; Sandrini G; Nappi G
J Headache Pain; 2015; 16():532. PubMed ID: 26018292
[TBL] [Abstract][Full Text] [Related]
4. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).
Stokes M; Becker WJ; Lipton RB; Sullivan SD; Wilcox TK; Wells L; Manack A; Proskorovsky I; Gladstone J; Buse DC; Varon SF; Goadsby PJ; Blumenfeld AM
Headache; 2011; 51(7):1058-77. PubMed ID: 21762134
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect costs of cluster headache: a prospective analysis in a tertiary level headache centre.
Negro A; Sciattella P; Spuntarelli V; Martelletti P; Mennini FS
J Headache Pain; 2020 May; 21(1):44. PubMed ID: 32366217
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
Munakata J; Hazard E; Serrano D; Klingman D; Rupnow MF; Tierce J; Reed M; Lipton RB
Headache; 2009 Apr; 49(4):498-508. PubMed ID: 19245386
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study.
Pradalier A; Auray JP; El Hasnaoui A; Alzahouri K; Dartigues JF; Duru G; Henry P; Lantéri-Minet M; Lucas C; Chazot G; Gaudin AF
Pharmacoeconomics; 2004; 22(15):985-99. PubMed ID: 15449963
[TBL] [Abstract][Full Text] [Related]
8. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).
Bloudek LM; Stokes M; Buse DC; Wilcox TK; Lipton RB; Goadsby PJ; Varon SF; Blumenfeld AM; Katsarava Z; Pascual J; Lanteri-Minet M; Cortelli P; Martelletti P
J Headache Pain; 2012 Jul; 13(5):361-78. PubMed ID: 22644214
[TBL] [Abstract][Full Text] [Related]
9. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
[TBL] [Abstract][Full Text] [Related]
10. Similarities and differences between chronic migraine and episodic migraine.
Ferrari A; Leone S; Vergoni AV; Bertolini A; Sances G; Coccia CP; Ottani A; Pinetti D; Sternieri E
Headache; 2007 Jan; 47(1):65-72. PubMed ID: 17355496
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Buse DC; Saiers J; Serrano D; Reed ML
J Med Econ; 2013; 16(4):490-9. PubMed ID: 23356422
[TBL] [Abstract][Full Text] [Related]
12. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
Serrano D; Manack AN; Reed ML; Buse DC; Varon SF; Lipton RB
Value Health; 2013; 16(1):31-8. PubMed ID: 23337213
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs among patients with chronic migraine, episodic migraine, and tension-type headache enrolled in commercial insurance plans.
Shao Q; Rascati KL; Barner JC; Lawson KA; Sonawane KB; Rousseau JF
Headache; 2022 Feb; 62(2):141-158. PubMed ID: 35156215
[TBL] [Abstract][Full Text] [Related]
14. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.
Hansson-Hedblom A; Axelsson I; Jacobson L; Tedroff J; Borgström F
J Headache Pain; 2020 Aug; 21(1):99. PubMed ID: 32787820
[TBL] [Abstract][Full Text] [Related]
15. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
16. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey.
Messali A; Sanderson JC; Blumenfeld AM; Goadsby PJ; Buse DC; Varon SF; Stokes M; Lipton RB
Headache; 2016 Feb; 56(2):306-22. PubMed ID: 26833083
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme.
Ueda K; Ye W; Lombard L; Kuga A; Kim Y; Cotton S; Jackson J; Treuer T
J Headache Pain; 2019 Jun; 20(1):68. PubMed ID: 31174464
[TBL] [Abstract][Full Text] [Related]
18. Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States.
Dodick DW; Reed ML; Lee L; Balkaran BL; Umashankar K; Parikh M; Gandhi P; Buse DC
Headache; 2024 Apr; 64(4):361-373. PubMed ID: 38523435
[TBL] [Abstract][Full Text] [Related]
19. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design.
Serrano D; Lipton RB; Scher AI; Reed ML; Stewart WBF; Adams AM; Buse DC
J Headache Pain; 2017 Oct; 18(1):101. PubMed ID: 28980171
[TBL] [Abstract][Full Text] [Related]
20. The Burden of Illness of Migraine in Canada: New Insights on Humanistic and Economic Cost.
Amoozegar F; Khan Z; Oviedo-Ovando M; Sauriol S; Rochdi D
Can J Neurol Sci; 2022 Mar; 49(2):249-262. PubMed ID: 33875042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
